Abstract
In the last 12 years, data has accumulated supporting an important role for hyperglycemia in the development of diabetic nephropathy, and in the same period identification and characterization of renal glucose transporters has expanded rapidly. This new knowledge concerning glucose transporters is now being used to determine the roles they may play in diabetic kidney disease. Recent studies of renal glucose transporters have characterized their responses to diabetes, and their potential roles in the diabetic kidney. Glucose transporters have been shown to be rate-limiting for mesangial cell glucose uptake, glucose metabolism and extracellular matrix (ECM) production by these cells. Furthermore, increased renal GLUT1 has been proposed to play an important role in the development of diabetic glomerulosclerosis. Recent data suggest increased GLUT8 in podocytes may contribute to diabetic glomerular disease as well. Renal tubular glucose transporter expression is also altered in diabetes, responding to the increased need for glucose reabsorption . However, further investigation is required to determine the potential roles of these glucose transporters in the interstitial kidney disease associated with diabetes.
Keywords: Glucose transporter, GLUT, SGLT, diabetic nephropathy, mesangial cell
Current Enzyme Inhibition
Title: Glucose Transporters in Normal and Diabetic Kidneys
Volume: 2 Issue: 3
Author(s): Charles W. Heilig and Youli Wang
Affiliation:
Keywords: Glucose transporter, GLUT, SGLT, diabetic nephropathy, mesangial cell
Abstract: In the last 12 years, data has accumulated supporting an important role for hyperglycemia in the development of diabetic nephropathy, and in the same period identification and characterization of renal glucose transporters has expanded rapidly. This new knowledge concerning glucose transporters is now being used to determine the roles they may play in diabetic kidney disease. Recent studies of renal glucose transporters have characterized their responses to diabetes, and their potential roles in the diabetic kidney. Glucose transporters have been shown to be rate-limiting for mesangial cell glucose uptake, glucose metabolism and extracellular matrix (ECM) production by these cells. Furthermore, increased renal GLUT1 has been proposed to play an important role in the development of diabetic glomerulosclerosis. Recent data suggest increased GLUT8 in podocytes may contribute to diabetic glomerular disease as well. Renal tubular glucose transporter expression is also altered in diabetes, responding to the increased need for glucose reabsorption . However, further investigation is required to determine the potential roles of these glucose transporters in the interstitial kidney disease associated with diabetes.
Export Options
About this article
Cite this article as:
Heilig W. Charles and Wang Youli, Glucose Transporters in Normal and Diabetic Kidneys, Current Enzyme Inhibition 2006; 2 (3) . https://dx.doi.org/10.2174/157340806777934757
DOI https://dx.doi.org/10.2174/157340806777934757 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Uric Acid Metabolism in Pre-hypertension and the Metabolic Syndrome
Current Vascular Pharmacology Therapeutic Potential of Cannabinoids in the Treatment of Neuroinflammation Associated with Parkinsons Disease
Mini-Reviews in Medicinal Chemistry Novel Approach to Cardiovascular Diseases: A Promising Probability of (Pro)Renin Receptor [(P)RR]
Current Pharmaceutical Design Epigenetic Effects of Cadmium in Cancer: Focus on Melanoma
Current Genomics Pigment Epithelium-derived Factor (PEDF) and Cardiometabolic Disorders
Current Pharmaceutical Design The Rationale for Comparative Studies of Accelerated Atherosclerosis in Rheumatic Diseases
Current Vascular Pharmacology Jak2 and Reactive Oxygen Species: A Complex Relationship
Current Chemical Biology Role of AGEs in Diabetic Nephropathy
Current Pharmaceutical Design Novel Colchicine Derivatives and their Anti-cancer Activity
Current Topics in Medicinal Chemistry Challenges for Gene Therapy of Type 1 Diabetes
Current Gene Therapy Recent Advances in Endocrine Metabolic Immune Disorders Drug Targeting: An Editorial Overview
Endocrine, Metabolic & Immune Disorders - Drug Targets Sirolimus Early Graft Nephrotoxicity: Clinical and Experimental Data
Current Drug Safety Antiplatelet Treatment in Ischemic Stroke Treatment
Current Topics in Medicinal Chemistry Dipeptidyl-peptidase 4 Inhibition: Linking Metabolic Control to Cardiovascular Protection
Current Pharmaceutical Design Hypertension to Heart Failure: New Developmental Strategies do not Cross a Clinical and Therapeutic Divide
Current Pharmaceutical Design Editorial (Thematic Issue: Anderson Fabry Disease: A Multiorgan Metabolic Disease Susceptible of Treatment)
Current Pharmaceutical Design Flavonoids as Sirtuin Modulators
Current Topics in Medicinal Chemistry Benefits of SGLT2 Inhibitors Beyond Glycemic Control – A Focus on Metabolic, Cardiovascular and Renal Outcomes
Current Diabetes Reviews Pregnancy in Type 2 Diabetes Mellitus - Problems & Promises
Current Diabetes Reviews Resurgence of Herbal Antihypertensives in Management of Hypertension
Current Hypertension Reviews